Target Validation Information
Target ID T73992
Target Name Beta-secretase
Target Type
Clinical Trial
Drug Potency against Target GRL-7234 Drug Info IC50 = 39 nM [1]
KUSHENOL A Drug Info IC50 = 2600 nM [2]
OM00-3 Drug Info IC50 = 6 nM [3]
KURARINONE Drug Info IC50 = 3300 nM [2]
(2S)-2'-methoxy kurarinone Drug Info IC50 = 6700 nM [2]
Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe Drug Info Ki = 0.3 nM [4]
(-)-CATECHINGALLATE Drug Info IC50 = 6000 nM [5]
GSK-188909 Drug Info IC50 = 30 nM [6]
DIOXINODEHYDROECKOL Drug Info IC50 = 5350 nM [7]
LEACHIANONE A Drug Info IC50 = 8400 nM [2]
TRIPHLOROETHOL A Drug Info IC50 = 11680 nM [7]
DIECKOL Drug Info IC50 = 2210 nM [7]
AP-2243 Drug Info IC50 = 238 nM [8]
Bis-7-tacrine Drug Info IC50 = 7500 nM [9]
CTS-21166 Drug Info IC50 = 0.12~20 nM/L [10]
PHLOROFUCOFUROECKOL A Drug Info IC50 = 2130 nM [7]
5,5-Diphenyl-2-iminohydantoin Drug Info IC50 = 12000 nM [11]
Carbocyclic Peptidomimetic Drug Info IC50 = 16 nM [12]
Eckol Drug Info IC50 = 12200 nM [7]
7-Phloroethol Drug Info IC50 = 8590 nM [7]
Action against Disease Model CTS-21166 CTS-21166 has cellular activity of IC50 = 1.2-3.6 nM, reduced brain A|??levels by over 35% and plaque load by 40%. [13] Drug Info
The Effect of Target Knockout, Knockdown or Genetic Variations secretase knockout mice are de?cient in Abetat production;the knockout mice are normal in terms of gross morphology and anatomy,tissue histology, hematology and clinical chemistry [1]
References
REF 1J Med Chem. 2007 May 17;50(10):2399-407. Epub 2007 Apr 14.Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
REF 2Bioorg Med Chem. 2008 Jul 15;16(14):6669-74. Epub 2008 Jun 5.BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens.
REF 3Bioorg Med Chem. 2007 Jun 15;15(12):4136-43. Epub 2007 Mar 30.Synthesis and biological evaluation of phosphino dipeptide isostere inhibitor of human beta-secretase (BACE1).
REF 4J Med Chem. 2004 Nov 4;47(23):5791-7.Efficient evaluation of binding free energy using continuum electrostatics solvation.
REF 5Bioorg Med Chem Lett. 2003 Nov 17;13(22):3905-8.Green tea catechins as a BACE1 (beta-secretase) inhibitor.
REF 6Bioorg Med Chem Lett. 2009 Jul 1;19(13):3664-8. Epub 2009 Apr 17.Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
REF 7Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. Epub 2010 Apr 24.Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity.
REF 8Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6. Epub 2007 Oct 4.Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.
REF 9J Med Chem. 2009 Sep 10;52(17):5365-79.Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
REF 10beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):399-408. doi: 10.1016/j.nurt.2008.05.007.
REF 11J Med Chem. 2010 Feb 11;53(3):951-65.Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation.
REF 12J Med Chem. 2005 Aug 11;48(16):5175-90.Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics.
REF 13Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int J Clin Exp Pathol. 2010 Jul 8;3(6):618-28.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.